Inventiva

Inventiva

Yahoo Finance • 16 days ago

Claret Capital Partners participates in €130m financing for Inventiva

Claret Capital Partners participates in €130m financing for Inventiva Inventiva is a clinical biopharmaceutical company developing an oral treatment for chronic liver disease, MASH Claret Capital Partners is providing growth funding of €4... Full story

Yahoo Finance • 16 days ago

Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development

Claret Capital Partners participates in €130m financing for Inventiva Inventiva is a clinical biopharmaceutical company developing an oral treatment for chronic liver disease, MASH Claret Capital Partners is providing growth funding of €4... Full story

Yahoo Finance • 19 days ago

Inventiva announces Repayment of EIB Loans, Repurchase of a portion of EIB Warrants and the Issuance of the first two tranches under New Debt Financing

Repaid in full the existing EIB Loans1 in an amount of approximately €62 million and completed repurchase of all 2,266,023 existing EIB Tranche A Warrants and 700,000 of existing EIB Tranche B Warrants2 (corresponding to approximately 22.7... Full story

Yahoo Finance • 19 days ago

Inventiva annonce le Remboursement des Prêts BEI, le Rachat d'une partie des BSA BEI et l'émission des deux premières tranches dans le cadre du Nouveau Financement

Remboursement intégral des Prêts BEI existants1 d'un montant d'environ 62 millions d'euros et finalisation du rachat de tous les 2,266,023 BSA Tranche A BEI existants et de 700.000 BSA Tranche B BEI existants2 (correspondant à environ 22,7... Full story

Yahoo Finance • 2 months ago

Inventiva to Present Abstracts at the EASL Congress 2026

Daix (France), New York City (New York, United States), May 13, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for t... Full story

Yahoo Finance • 2 months ago

Inventiva présentera plusieurs abstracts lors de l’EASL Congress 2026

Daix (France), New York City (New York, Etats-Unis), le 13 mai 2026 – Inventiva (Euronext Paris et NASDAQ: IVA) (« Inventiva » ou la « Société »), société biopharmaceutique au stade clinique spécialisée dans le développement de thérapies p... Full story

Yahoo Finance • 3 months ago

How The Inventiva (ENXTPA:IVA) Story Is Shifting With Lanifibranor And Analyst Revisions

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Inventiva’s updated analyst narrative now reflects a Fair Value move from €8.98 to about €10.00, a... Full story

Yahoo Finance • 3 months ago

Inventiva reports 2025 full year results and provides a business update

Revenues of €4.5 million for the full year of 2025Cash and cash equivalents at €99.3 million, and €131.6 million in short-term deposits1 as at December 31, 2025Completed a U.S. registered public offering for gross proceeds of approximately... Full story

Yahoo Finance • 3 months ago

Inventiva publie ses résultats financiers annuels 2025 et fait le point sur son activité

Chiffre d'affaires de 4,5 millions d'euros pour l’année 2025Trésorerie et équivalents de trésorerie à 99,3 millions d’euros et 131,6 millions d'euros en dépôts à court terme1 au 31 décembre 2025Réalisation d'une offre au public aux États-U... Full story

Yahoo Finance • 7 months ago

Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025

Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatme... Full story

Yahoo Finance • 7 months ago

Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunie le 27 novembre 2025

Daix (France), New York City (New York, Etats-Unis), le 28 novembre 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour l... Full story

Yahoo Finance • 7 months ago

Inventiva S.A. reports nine-months results

* Inventiva S.A. press release [https://seekingalpha.com/pr/20317481-inventiva-reports-2025-third-quarter-financial-information] (OTCPK:IVEVF [https://seekingalpha.com/symbol/IVEVF]): Revenues of €4.5 million for the first nine months of... Full story

Yahoo Finance • 7 months ago

Inventiva S.A reports 9M results

* Inventiva S.A (IVA [https://seekingalpha.com/symbol/IVA]): Revenues for the first nine months of 2025 amounted to €4.5 million, compared to none generated for the same period in 2024. * Cash and cash equivalents at €97.6 million, and... Full story

Yahoo Finance • 7 months ago

Inventiva reports 2025 Third Quarter Financial Information¹

Cash and cash equivalents at €97.6 million, and €24.7 million in short-term deposits2 as of September 30, 2025.Revenues of €4.5 million for the first nine months of 2025.Cash runway expected until the end of the first quarter of 20273, inc... Full story

Yahoo Finance • 7 months ago

Inventiva publie ses informations financières du 3ème trimestre 2025¹

Trésorerie et équivalents de trésorerie à 97,6 millions d’euros, et 24,7 millions d’euros en dépôts à court terme2 au 30 septembre.Chiffre d’affaires de 4,5 millions d’euros sur les neuf premiers mois de 2025.Horizon de trésorerie prévue j... Full story

Yahoo Finance • 7 months ago

Inventiva announces full exercise of Underwriters’ Option, bringing proceeds of Offering to approximately $172.5M

Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies... Full story

Yahoo Finance • 7 months ago

Inventiva annonce l’exercice intégral de l’Option des Banques portant le montant de l'Offre à environ 172,5 millions de dollars

Daix (France), New York City (New York, États-Unis), le 17 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour l... Full story

Yahoo Finance • 8 months ago

Inventiva announces trading resumption of its ordinary shares on Euronext Paris

Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies... Full story

Yahoo Finance • 8 months ago

Inventiva annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris

Daix (France), New York City (New York, États-Unis), le 13 novembre 2025 – Inventiva (Euronext Paris et Nasdaq : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour l... Full story

Yahoo Finance • 8 months ago

Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares

Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies... Full story